LEO Pharma Inc., a wholly owned U.S. subsidiary of LEO Pharma A/S, today announced a new Taclonex (calcipotriene and betamethasone dipropionate) topical suspension indication for a topical combination treatment of plaque psoriasis of the scalp in patients 12 to 17 years – the first indication for adolescent patients aged 12 years and older with scalp plaque psoriasis on the market.

Taclonex topical suspension is a first-line, once-daily combination product indicated for treatment of both scalp and body plaque psoriasis in adults age 18 and above for up to eight weeks, and now for the treatment of plaque psoriasis of the scalp in pediatric patients 12 to 17 years for the same period.

For more details, go to: https://in.finance.yahoo.com/news/leo-pharma-inc-announced-taclonex-130200876.html